JPH08198768A - Diabetes-treating agent - Google Patents
Diabetes-treating agentInfo
- Publication number
- JPH08198768A JPH08198768A JP7027337A JP2733795A JPH08198768A JP H08198768 A JPH08198768 A JP H08198768A JP 7027337 A JP7027337 A JP 7027337A JP 2733795 A JP2733795 A JP 2733795A JP H08198768 A JPH08198768 A JP H08198768A
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- glibenclamide
- weight
- treating agent
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 20
- 229960004580 glibenclamide Drugs 0.000 claims abstract description 14
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 241001061264 Astragalus Species 0.000 claims description 8
- 235000006533 astragalus Nutrition 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 210000004233 talus Anatomy 0.000 claims description 8
- 239000003472 antidiabetic agent Substances 0.000 claims description 7
- 229940125708 antidiabetic agent Drugs 0.000 claims description 7
- 241000220259 Raphanus Species 0.000 claims 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 13
- 208000008454 Hyperhidrosis Diseases 0.000 abstract description 6
- 208000013016 Hypoglycemia Diseases 0.000 abstract description 6
- 206010040026 Sensory disturbance Diseases 0.000 abstract description 6
- 206010044565 Tremor Diseases 0.000 abstract description 6
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 6
- 230000035900 sweating Effects 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 2
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006187 pill Substances 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 235000003642 hunger Nutrition 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 3
- 206010020710 Hyperphagia Diseases 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- 208000037063 Thinness Diseases 0.000 description 3
- 239000003538 oral antidiabetic agent Substances 0.000 description 3
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 208000022530 polyphagia Diseases 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
- 208000016255 tiredness Diseases 0.000 description 3
- 230000003867 tiredness Effects 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000276616 Cichlidae Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 244000299906 Cucumis sativus var. sativus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- -1 that is Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】この発明は、血糖値を下げて糖尿
病の症状を軽減させることができる糖尿病治療剤に関す
るものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a therapeutic agent for diabetes which can lower the blood glucose level and reduce the symptoms of diabetes.
【０００２】[0002]
【従来の技術】従来の糖尿病の治療薬としては、インス
リンや経口血糖降下剤等の薬剤が使われている。しかし
ながらインスリンは注射剤としてのみ有効であった。2. Description of the Related Art As conventional therapeutic agents for diabetes, drugs such as insulin and oral hypoglycemic agents have been used. However, insulin was only effective as an injection.
【０００３】上記経口血糖降下剤、すなわち血糖値を下
げて糖尿病の症状を軽減させることができる治療剤とし
ては、グリベンクラミド等のスルホニル尿素薬、ビグア
ナイド系、エパルレスタット等が知られている。その
内、グリベンクラミド等のスルホニル尿素薬は、すい臓
のランゲルハンス島β細胞を刺激してインスリンの分泌
を増加させ、血糖値を低下させる。また、体内でインス
リンの作用を増強させる働きもある。As the above-mentioned oral hypoglycemic agents, that is, therapeutic agents capable of lowering blood glucose levels and alleviating the symptoms of diabetes, sulfonylurea drugs such as glibenclamide, biguanides, epalrestat and the like are known. Among them, sulfonylurea drugs such as glibenclamide stimulate Langerhans islet β cells in the pancreas to increase insulin secretion and lower blood glucose level. It also has the function of enhancing the action of insulin in the body.
【０００４】[0004]
【発明が解決しようとする課題】しかしながら上記従来
のグリベンクラミドからなる糖尿病治療剤においては、
脱力感や高度の空腹感、発汗、振戦、知覚障害等の副作
用が知られている。特に重篤な低血糖症が起きることの
あることがあり、服用には細心の注意を払わなければな
らなかった。However, in the above-mentioned conventional therapeutic agents for diabetes consisting of glibenclamide,
Side effects such as weakness, high hunger, sweating, tremor, and sensory disturbance are known. Especially severe hypoglycemia may occur, so that it was necessary to take extreme caution in taking the drug.
【０００５】また経口血糖降下剤は糖尿病昏睡および若
年型糖尿病に対しては無効であるという制約があった。There is also a limitation that oral hypoglycemic agents are ineffective against diabetic coma and juvenile diabetes.
【０００６】この発明の糖尿病治療剤は従来例の上記欠
点を解消しようとするもので、脱力感や高度の空腹感、
発汗、振戦、知覚障害、重篤な低血糖症等の副作用を軽
減させることができる糖尿病治療剤を提供しようとする
ものである。The anti-diabetic agent of the present invention is intended to solve the above-mentioned drawbacks of the conventional examples.
It is an object of the present invention to provide a therapeutic agent for diabetes that can reduce side effects such as sweating, tremor, sensory disturbance, and severe hypoglycemia.
【０００７】[0007]
【課題を解決するための手段】すなわちこの発明の糖尿
病治療剤は、天花粉（テンカフン）３５重量％、生薬地
黄（ジオウ）３５重量％、黄耆（オウギ）３０重量％お
よび微量のグリベンクラミドを混合したことを特徴とす
るものである。[Means for Solving the Problems] That is, the anti-diabetic agent of the present invention comprises 35% by weight of sky pollen (Tenkafun), 35% by weight of crude herb (Diou), 30% by weight of Astragalus sinensis (Augi) and a small amount of glibenclamide. It is characterized by that.
【０００８】またこの発明の糖尿病治療剤は、天花粉
（テンカフン）、生薬地黄（ジオウ）、黄耆（オウギ）
の総量に対し、約１／１０００のグリベンクラミドを混
合したことをも特徴としている。The antidiabetic agent of the present invention is also known as Heavenly Pollen (Tenkafun), Crude Medicinal Yellow (Ziou), Radix Astragalus (Ougi).
It is also characterized in that about 1/1000 of glibenclamide was mixed with respect to the total amount.
【０００９】この発明において使用する天花粉（テンカ
フン）は、キカラスウリの根から採った白色の澱粉で、
通常汗疹に撒布し、また化粧用とし、または煎剤として
鎮咳・解熱・利尿に用いるものである。The heavenly pollen (tenkafun) used in the present invention is a white starch taken from the roots of Cichlid cucumber,
It is usually applied to eczema, used as a cosmetic or as a decoction for antitussive, antipyretic, and diuretic.
【００１０】生薬地黄（ジオウ）は、ゴマノハグサ科の
多年草である地黄の根茎で補血に効があることが知られ
ている。[0010] Crude medicinal ground yellow (Ziou) is known to have an effect on blood supplementation in the rhizome of the ground yellow, which is a perennial plant of the family Scutellariae.
【００１１】黄耆（オウギ）は、体力が低下した人や、
疲労しやすい場合に服用することが知られており、虚弱
体質、病後の衰弱、寝汗等に効があるとされている。[0011] Astragalus (Ougi) is a person whose physical strength has decreased,
It is known to be taken when tired easily, and it is said to be effective for weak constitution, weakness after illness, night sweats and the like.
【００１２】グリベンクラミドは、スルホニル尿素薬で
あり、すい臓のランゲルハンス島β細胞を刺激してイン
スリンの分泌を増加させ、血糖値を低下させるものであ
る。また、体内でインスリンの作用を増強させる働きも
ある。Glibenclamide is a sulfonylurea drug, which stimulates Langerhans islet β cells in the pancreas to increase insulin secretion and lowers blood glucose level. It also has the function of enhancing the action of insulin in the body.
【００１３】[0013]
【作用】この発明の糖尿病治療剤は以上のように構成し
たので、血糖値を降下させる作用があることはもちろ
ん、脱力感や高度の空腹感、発汗、振戦、知覚障害、重
篤な低血糖症等の副作用を軽減させることができる糖尿
病治療剤を提供することができる。Since the therapeutic agent for diabetes of the present invention is constituted as described above, it not only has the effect of lowering the blood glucose level, but also has a feeling of weakness, a high degree of hunger, sweating, tremor, sensory disturbance, and a serious low level. It is possible to provide a therapeutic agent for diabetes that can reduce side effects such as blood sugar.
【００１４】またこの発明の糖尿病治療剤は、唾液を生
じることができ、多飲症、多尿症、多食症、やせ気味、
疲れ、無気力、睡眠不足、腰痛、尿糖値や血糖値が高い
症状に有効である。The anti-diabetic agent of the present invention is capable of producing saliva, polydipsia, polyuria, polyphagia, leanness,
It is effective for tiredness, lethargy, lack of sleep, low back pain, and high urinary glucose and blood sugar levels.
【００１５】[0015]
【実施例】以下、この発明の糖尿病治療剤の一実施例を
詳細に説明する。 （実施例１）粉末状態の天花粉（テンカフン）３５重量
％、生薬地黄（ジオウ）３５重量％、黄耆（オウギ）３
０重量％と、これらの総量に対し、１／１０００のグリ
ベンクラミドを混合して少量の水で練って製剤し、乾燥
して丸剤を調合した。得た丸剤は黒色の約０．２５ｇの
粒状であった。EXAMPLE An example of the therapeutic agent for diabetes of the present invention will be described in detail below. (Example 1) 35% by weight of powdered heaven pollen (Tenkafun), 35% by weight of herbal medicine (Zhou), Astragalus (Astragalus) 3
0% by weight and 1/1000 of glibenclamide with respect to the total amount thereof were mixed, kneaded with a small amount of water to prepare a formulation, and dried to prepare a pill. The obtained pills were black and had a particle size of about 0.25 g.
【００１６】なお上記丸剤中のグリベンクラミド量は、
丸剤約０．２５ｇに対し、０．２５ｍｇの配合量であっ
た。The amount of glibenclamide in the above pills is
The compounding amount was 0.25 mg based on about 0.25 g of pills.
【００１７】この丸剤を血糖値の高い糖尿病患者に１日
３回、さましたお湯で少量を服用させ、その後約５個か
ら１０個（約１．２５ｇ〜２．５ｇ）に増やして治療効
果が現われる時まで経口投与を続け、血糖値に効果が見
られた後、毎日約２回の維持剤量に減らした。 （実施例２）天花粉（テンカフン）３５重量％、生薬地
黄（ジオウ）３５重量％、黄耆（オウギ）３０重量％
と、これらの総量に対し、１／１０００のグリベンクラ
ミドを混合してアルコールで調製し、溶液を調合した。
得た溶液約１０〜３０倍に希釈して注射液を得た。This pill is used by diabetic patients with high blood sugar level three times a day with a small amount of hot water, and then increased from about 5 to 10 (about 1.25 g to 2.5 g) for therapeutic effect. Oral administration was continued until the onset of the symptoms appeared, and after the effect on the blood glucose level was observed, the amount of the maintenance agent was reduced to about twice daily. (Example 2) Heaven pollen (Tenkafun) 35% by weight, crude drug ground yellow (Diou) 35% by weight, Astragalus (Astragalus) 30% by weight
Then, 1/1000 of glibenclamide was mixed with the total amount of these to prepare with alcohol to prepare a solution.
The obtained solution was diluted about 10 to 30 times to obtain an injection solution.
【００１８】なお上記注射液中のグリベンクラミド量
は、注射液全体に対し、１／１０００の配合量であっ
た。The amount of glibenclamide in the above injection solution was 1/1000 of the total amount of the injection solution.
【００１９】この注射液を血糖値の高い糖尿病患者に１
日数回皮下ないし筋肉注射し、治療効果が現われる時ま
で注射による投与を続け、血糖値に効果が見られた後、
毎日約２回の維持剤量に減らした。This injection solution is used for diabetic patients with high blood sugar level.
After subcutaneous or intramuscular injection several times a day, continue administration by injection until the therapeutic effect appears, and after the effect on blood glucose level is seen,
The amount of maintenance agent was reduced to about twice daily.
【００２０】なお上記注射液を血糖値の高い糖尿病患者
に１日数回、使用量を調整して静脈注射ないし点滴して
も、同様の効果が得られた。 〔薬理学的性質〕上記投与の結果、血糖値に著しい改善
が見られたほか、服用時に脱力感や高度の空腹感、発
汗、振戦、知覚障害、重篤な低血糖症等の副作用がほと
んど見られなかった。The same effect was obtained by intravenously injecting or instilling the above injection solution to a diabetic patient having a high blood glucose level several times a day by adjusting the use amount. [Pharmacological properties] As a result of the above administration, a significant improvement in blood glucose was observed, and side effects such as weakness and a high degree of hunger, sweating, tremor, sensory disturbance, and severe hypoglycemia were observed during administration. It was hardly seen.
【００２１】しかも、服用時に唾液を生じ、多飲症、多
尿症、多食症、やせ気味、疲れ、無気力、睡眠不足、腰
痛等の症状がなく、普段の生活にも何ら支障のないほど
の症状の改善が見られた。もちろん食事療法、運動療法
と組み合わせることが重要である。 〔治療学的応用〕製品は例えば丸剤の形で投薬され、血
糖値の高い糖尿病患者に試験的に投与し、その後１日３
回、約５個から１０個（約１．２５ｇ〜２．５ｇ）服用
させて治療効果が現われる時まで経口投与される。 〔毒物学的性質〕この発明において、グリベンクラミド
の使用量は厳格に制限することが必要であり、糖尿病治
療剤の使用量が適正な量を越えた場合は重篤な低血糖症
が起きることがある。Moreover, saliva is produced when the drug is taken, and there are no symptoms such as polydipsia, polyuria, polyphagia, leanness, tiredness, lethargy, sleep deprivation, and backache, and there is no problem in daily life. The symptoms were improved. Of course, it is important to combine it with diet therapy and exercise therapy. [Therapeutic Application] The product is administered, for example, in the form of pills, and is administered on a trial basis to diabetic patients with high blood glucose levels, and then 3 days a day.
About 5 to 10 doses (about 1.25 g to 2.5 g) are orally administered until the therapeutic effect appears. [Toxicological Properties] In the present invention, the use amount of glibenclamide needs to be strictly limited, and when the use amount of the antidiabetic agent exceeds an appropriate amount, serious hypoglycemia may occur. is there.
【００２２】[0022]
【発明の効果】この発明の糖尿病治療剤は以上のように
構成したので、血糖値を降下させる作用があることはも
ちろん、脱力感や高度の空腹感、発汗、振戦、知覚障
害、重篤な低血糖症等の副作用を軽減させることができ
る糖尿病治療剤を提供することができる。EFFECTS OF THE INVENTION Since the therapeutic agent for diabetes of the present invention is constituted as described above, it not only has the effect of lowering the blood glucose level, but also has a feeling of weakness, a high degree of hunger, sweating, tremor, sensory disturbance, and seriousness. It is possible to provide a therapeutic agent for diabetes that can reduce side effects such as various hypoglycemia.
【００２３】またこの発明の糖尿病治療剤は、唾液を生
じることができ、多飲症、多尿症、多食症、やせ気味、
疲れ、無気力、睡眠不足、腰痛、尿糖や血糖が高い症状
に有効である。The antidiabetic agent of the present invention is capable of producing saliva, polydipsia, polyuria, polyphagia, leanness,
It is effective for tiredness, lethargy, lack of sleep, low back pain, and high urinary glucose and blood sugar.
Claims (2)
地黄（ジオウ）３５重量％、黄耆（オウギ）３０重量％
および微量のグリベンクラミドを混合したことを特徴と
する糖尿病治療剤。1. Ten percent pollen (Tenkafun) 35% by weight, Crude medicinal yellow (Diou) 35% by weight, Astragalus (Ougi) 30% by weight
And a therapeutic agent for diabetes characterized by mixing a small amount of glibenclamide.
ウ）、黄耆（オウギ）の総量に対し、約１／１０００の
グリベンクラミドを混合してなる請求項１に記載の糖尿
病治療剤。2. The anti-diabetic agent according to claim 1, which is obtained by mixing about 1/1000 of glibenclamide with respect to the total amount of sky pollen (tenkafun), crude drug ground yellow (dio), and yellow radish (Ougi).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7027337A JPH08198768A (en) | 1995-01-20 | 1995-01-20 | Diabetes-treating agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7027337A JPH08198768A (en) | 1995-01-20 | 1995-01-20 | Diabetes-treating agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08198768A true JPH08198768A (en) | 1996-08-06 |
Family
ID=12218255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7027337A Pending JPH08198768A (en) | 1995-01-20 | 1995-01-20 | Diabetes-treating agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH08198768A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973831A (en) * | 2012-12-14 | 2013-03-20 | 贵州信邦制药股份有限公司 | Preparation method of Huaqi preparation |
| CN104491343A (en) * | 2014-12-08 | 2015-04-08 | 黄平县兴且民族民间中草医药科学发展有限责任公司 | Traditional Chinese medicine preparation for treating diabetes |
| CN104509855A (en) * | 2014-12-13 | 2015-04-15 | 兰州红菌生物技术有限责任公司 | Auxiliary hypoglycemic composition and preparation method thereof |
| CN104873837A (en) * | 2015-06-02 | 2015-09-02 | 徐倩 | Traditional Chinese medicine granular preparation and preparing method thereof |
| CN104873739A (en) * | 2015-06-16 | 2015-09-02 | 徐倩 | Traditional Chinese medicine preparation for treating diabetes and preparation method thereof |
| CN104873877A (en) * | 2015-06-09 | 2015-09-02 | 张保全 | Blood-sugar-lowering and body-constitution-conditioning traditional Chinese medicinal composition |
| CN105147979A (en) * | 2015-09-10 | 2015-12-16 | 桂林盛兴电子科技有限公司 | Traditional Chinese medicine composition for treating diabetes as well as preparation method and medicine thereof |
| CN105147994A (en) * | 2015-09-10 | 2015-12-16 | 桂林盛兴电子科技有限公司 | Traditional Chinese medicine preparation for treating diabetes and preparation method thereof |
| CN105876802A (en) * | 2016-06-25 | 2016-08-24 | 聂超 | Traditional Chinese medicine health food product with efficacy of blood glucose reduction and preparation process of traditional Chinese medicine health food product |
| WO2019208700A1 (en) * | 2018-04-26 | 2019-10-31 | ゼリア新薬工業株式会社 | Dipeptide and pharmaceutical composition containing same |
-
1995
- 1995-01-20 JP JP7027337A patent/JPH08198768A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973831A (en) * | 2012-12-14 | 2013-03-20 | 贵州信邦制药股份有限公司 | Preparation method of Huaqi preparation |
| CN104491343A (en) * | 2014-12-08 | 2015-04-08 | 黄平县兴且民族民间中草医药科学发展有限责任公司 | Traditional Chinese medicine preparation for treating diabetes |
| CN104509855A (en) * | 2014-12-13 | 2015-04-15 | 兰州红菌生物技术有限责任公司 | Auxiliary hypoglycemic composition and preparation method thereof |
| CN104873837A (en) * | 2015-06-02 | 2015-09-02 | 徐倩 | Traditional Chinese medicine granular preparation and preparing method thereof |
| CN104873877A (en) * | 2015-06-09 | 2015-09-02 | 张保全 | Blood-sugar-lowering and body-constitution-conditioning traditional Chinese medicinal composition |
| CN104873739A (en) * | 2015-06-16 | 2015-09-02 | 徐倩 | Traditional Chinese medicine preparation for treating diabetes and preparation method thereof |
| CN105147979A (en) * | 2015-09-10 | 2015-12-16 | 桂林盛兴电子科技有限公司 | Traditional Chinese medicine composition for treating diabetes as well as preparation method and medicine thereof |
| CN105147994A (en) * | 2015-09-10 | 2015-12-16 | 桂林盛兴电子科技有限公司 | Traditional Chinese medicine preparation for treating diabetes and preparation method thereof |
| CN105876802A (en) * | 2016-06-25 | 2016-08-24 | 聂超 | Traditional Chinese medicine health food product with efficacy of blood glucose reduction and preparation process of traditional Chinese medicine health food product |
| WO2019208700A1 (en) * | 2018-04-26 | 2019-10-31 | ゼリア新薬工業株式会社 | Dipeptide and pharmaceutical composition containing same |
| JPWO2019208700A1 (en) * | 2018-04-26 | 2021-04-30 | ゼリア新薬工業株式会社 | Dipeptide and pharmaceutical composition containing it |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100353983C (en) | Chinese medicine preparation for reducing sugar | |
| CN101780261A (en) | Traditional Chinese medicine composition for treating toothache and preparation method thereof | |
| CN101773632B (en) | Chinese medicine composition for treating dizziness and preparation method thereof | |
| JPH08198768A (en) | Diabetes-treating agent | |
| CN105412858A (en) | Syrup and preparation method thereof | |
| CN101028446A (en) | Medicine for symptomatic dry eye | |
| CN1054528C (en) | Already prepared traditional Chinese medicine for treating psoriasis named "kangyinlin" | |
| CN102274417A (en) | Chinese patent medicament for treating aplastic anemia | |
| CN1864712A (en) | A Chinese medicine for treating rhinitis and preparation method thereof | |
| CN1277573C (en) | Medication for curing ulcerationd of oral cavity | |
| CN1533795A (en) | Chinese medicine for treating digestive ulcerating sore and its preparation method | |
| CN115089676B (en) | Application of swertia mileensis-containing traditional Chinese medicine compound composition in preparation of secondary prevention medicine for treating coronary heart disease | |
| CN101229221B (en) | Chinese traditional medicine for treating thromboangiitis obliterans and preparing method thereof | |
| CN112933122B (en) | Traditional Chinese medicine external medicine for treating recurrent oral ulcer | |
| CN111773292B (en) | Traditional Chinese medicine composition for treating herpes zoster as well as preparation method and application thereof | |
| CN1306830A (en) | Medicine for treating type II diabetes | |
| CN110680900B (en) | Medicine for treating recurrent oral ulcer and preparation method thereof | |
| CN101716321A (en) | Traditional Chinese medicine composition for treating heart vessel blockage stasis disease and preparation method thereof | |
| CN100364596C (en) | Compounded mongolia medicine for treating diabetes and preparing method | |
| CN1196953A (en) | Chinese patent drug for treating chronic bronchitis and asthma | |
| CN1289122C (en) | Medicinal composition for treating psoriasis and preparation method thereof | |
| CN108210594B (en) | Pharmaceutical composition with effects of ventilating lung, relieving cough, dispelling wind and astringing yin and preparation method and application thereof | |
| CN119405759A (en) | Composition for reducing uric acid and improving renal function, and preparation method, application and product thereof | |
| JPH07188043A (en) | Relieving agent of pain caused by zoster virus | |
| CN112843209A (en) | Traditional Chinese medicine composition for treating chronic dizziness and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060112 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060403 |